MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of 'France 2030', led by the Health Innovation Agency dedicated to ...

Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 ...

Partnerships in healthcare have never been more important. Through collaboration, industry specialists are increasingly bringing cutting-edge medical innovations and life-changing treatments to ...

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...

This significant milestone demonstrates the facility's advanced capabilities, operational efficiency, and technical expertise ...

Silo Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for mental health and chronic pain, announced in a recent letter to shareholders that it expects to submit an ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including ...

Corden Pharma Colorado Inc., a developer and manufacturer of peptide drug substances, has leased the 64,000-square-foot 5505 ...

Add Yahoo as a preferred source to see more of our stories on Google. LONDON, Dec 11 (Reuters) - Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research ...

TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal ...